Evidence map›Paper›PMID 42857042›Full record

ArticleACS organic & inorganic Au2026

Structured HTE Data and Integrated Bayesian Optimization Accelerate Scalable Amidation Process Development.

Jason M Stevens, Dung L Golden, Nikki Dare, Shubhangi Aggarwal, David Del Valle, Stacey DiSomma, Michael Eng, Ariel Furman, Lauren Grant, Diane Hendrix and 17 more

Abstract read
In one paragraph

Article in ACS organic & inorganic Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Jason M StevensChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0003-1671-1539
Dung L GoldenChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0002-9044-4873
Nikki DareACD/Laboratories Advanced Chemistry Development, 8 King Street East, Toronto, Ontario M5C 1B5, Canada.
Shubhangi AggarwalChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0001-7115-2931
David Del ValleChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0009-0008-0696-9257
Stacey DiSommaChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0001-9625-087X
Michael EngChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0003-2144-3057
Ariel FurmanChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0009-0000-3043-9637
Lauren GrantChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Diane HendrixPharmaceutical Development Information Technologies, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Bilal HoblosChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Jiajie HuoChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Mikalai MalashchonakACD/Laboratories Advanced Chemistry Development, 8 King Street East, Toronto, Ontario M5C 1B5, Canada.
Ketleine MillerPharmaceutical Development Information Technologies, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Emily MumfordChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Cheng PengChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0001-5680-1024
Lingxiang LuChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0001-9168-6121
Donggeon NamChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Frederick RobertsChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Victor RossoChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.ORCID https://orcid.org/0000-0002-1036-4153
Eric SaurerChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Sushant SinghPharmaceutical Development Information Technologies, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Dmitriy SnetkovACD/Laboratories Advanced Chemistry Development, 8 King Street East, Toronto, Ontario M5C 1B5, Canada.
Anton TerekhACD/Laboratories Advanced Chemistry Development, 8 King Street East, Toronto, Ontario M5C 1B5, Canada.
Alexander E WakedACD/Laboratories Advanced Chemistry Development, 8 King Street East, Toronto, Ontario M5C 1B5, Canada.
Michael WilliamsChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.
Chengmin ZhangChemical Process Development, Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the evolution of our early hit-identification workflow for reagent-mediated amidation reactions in support of commercial route development. Over the past decade, our strategy progressed from broad, exhaustive high-throughput experimentation (HTE) with limited data maturity to a modern, enterprise-scale digital platform that embeds data science tools directly into the experimental workflow. By tailoring Katalyst D2Da commercial electronic laboratory notebook (ELN) for HTE developed by ACD/Laboratorieswe established a structured, machine-readable data architecture and enabled seamless integration with the EDBO+ Bayesian optimization engine. Retrospective analysis of historical amidation data sets showed that, despite screening more than 60 reagents, only a small subset consistently translated to commercial processes. This insight motivated a streamlined workflow in which chemists begin with a focused survey of six reaction conditions rooted in empirical performance and commercial precedent, followed by Bayesian optimization within the ELN to identify optimal reagent/base/solvent combinations. This study highlights how treating reaction data as a digital assetFAIR, interoperable, and directly linked to optimization toolsaccelerates the transition from reaction screening to robust process development.

Indexed as

Artificial intelligencedata sciencehigh-throughput experimentationmachine learningreaction optimization

Identifiers

PMID42857042
PMCPMC13650955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.